Physician profile
Jamin Brown
NPI 1235242124
$17,751.49
in general payments reported to CMS, 2019-2025
19 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $722 · 2021: $2,000 · 2022: $11K · 2023: $1,095 · 2024: $1,371 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,274 · Consulting Fee: $1,000 · Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,273.52 |
| Consulting Fee | $1,000.00 |
| Food and Beverage | $510.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $14,306.97 | 2019-2022 | |
| Dutch Ophthalmic, USA | $2,377.22 | 2022-2024 | Eva, Combined Machine, Tissueblue |
| Alcon Vision LLC | $244.35 | 2022-2025 | Unity |
| Ocular Therapeutix, INC. | $197.60 | 2019 | |
| Astellas Pharma US INC | $148.85 | 2023-2025 | Izervay |
| Amgen INC. | $124.99 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $121.75 | 2019 | |
| Tearlab Corp | $77.22 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $61.20 | 2019-2025 | Eylea, Eylea Hd |
| Genentech, INC. | $58.71 | 2019 | |
| Allergan, INC. | $17.47 | 2019 | |
| Genentech USA, INC. | $15.16 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.